Comparing cancer to diabetes is a reach. The balancing of hormones in diabetes is difficult but nothing compared to the complexities of each individual patient's cancers.

Since here we're dealing with a non-targeted genetherapy with a relatively well understood metabolic pathway the extension to humans will be simpler. The actual vector of getting the genes in will be challenging to convert but once we have that, we can use it for many other gene therapies.